• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Nycomed Amersham Imaging taps CEO

Article

Anglo-Norwegian pharmaceutical company Nycomed Amersham of Buckinghamshire, U.K., has tapped John Padfield as CEO of its Nycomed Amersham Imaging contrast division. Padfield joins the company from U.K. pharmaceutical firm Chiroscience Group and

Anglo-Norwegian pharmaceutical company Nycomed Amersham of Buckinghamshire, U.K., has tapped John Padfield as CEO of its Nycomed Amersham Imaging contrast division. Padfield joins the company from U.K. pharmaceutical firm Chiroscience Group and will succeed Guy Marlow as chief of Nycomed Amersham’s global contrast business. Marlow is retiring later this year.

Related Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.